vs
Cytek Biosciences, Inc.（CTKB）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
Cytek Biosciences, Inc.的季度营收约是RHYTHM PHARMACEUTICALS, INC.的1.0倍（$62.1M vs $60.1M），Cytek Biosciences, Inc.净利率更高（-70.9% vs -92.6%，领先21.6%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（83.8% vs 8.1%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（43.8% vs 17.7%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
CTKB vs RYTM — 直观对比
营收规模更大
CTKB
是对方的1.0倍
$60.1M
营收增速更快
RYTM
高出75.7%
8.1%
净利率更高
CTKB
高出21.6%
-92.6%
两年增速更快
RYTM
近两年复合增速
17.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $60.1M |
| 净利润 | $-44.1M | $-55.6M |
| 毛利率 | 52.9% | 88.1% |
| 营业利润率 | -9.0% | -87.1% |
| 净利率 | -70.9% | -92.6% |
| 营收同比 | 8.1% | 83.8% |
| 净利润同比 | -557.1% | — |
| 每股收益（稀释后） | — | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBRYTM
| Q1 26 | — | $60.1M | ||
| Q4 25 | $62.1M | $57.3M | ||
| Q3 25 | $52.3M | $51.3M | ||
| Q2 25 | $45.6M | $48.5M | ||
| Q1 25 | $41.5M | $32.7M | ||
| Q4 24 | $57.5M | $41.8M | ||
| Q3 24 | $51.5M | $33.3M | ||
| Q2 24 | $46.6M | $29.1M |
净利润CTKBRYTM
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $-44.1M | $-47.5M | ||
| Q3 25 | $-5.5M | $-52.9M | ||
| Q2 25 | $-5.6M | $-46.6M | ||
| Q1 25 | $-11.4M | $-49.5M | ||
| Q4 24 | $9.6M | $-43.3M | ||
| Q3 24 | $941.0K | $-43.6M | ||
| Q2 24 | $-10.4M | $-32.3M |
毛利率CTKBRYTM
| Q1 26 | — | 88.1% | ||
| Q4 25 | 52.9% | 91.6% | ||
| Q3 25 | 52.7% | 89.3% | ||
| Q2 25 | 52.3% | 88.6% | ||
| Q1 25 | 48.6% | 88.8% | ||
| Q4 24 | 58.5% | 90.9% | ||
| Q3 24 | 56.3% | 88.5% | ||
| Q2 24 | 54.6% | 89.9% |
营业利润率CTKBRYTM
| Q1 26 | — | -87.1% | ||
| Q4 25 | -9.0% | -82.2% | ||
| Q3 25 | -17.6% | -102.6% | ||
| Q2 25 | -23.3% | -93.4% | ||
| Q1 25 | -36.1% | -143.7% | ||
| Q4 24 | 5.2% | -98.6% | ||
| Q3 24 | -8.2% | -132.0% | ||
| Q2 24 | -18.3% | -139.2% |
净利率CTKBRYTM
| Q1 26 | — | -92.6% | ||
| Q4 25 | -70.9% | -83.0% | ||
| Q3 25 | -10.5% | -103.1% | ||
| Q2 25 | -12.2% | -96.1% | ||
| Q1 25 | -27.5% | -151.4% | ||
| Q4 24 | 16.8% | -103.6% | ||
| Q3 24 | 1.8% | -131.2% | ||
| Q2 24 | -22.4% | -110.9% |
每股收益（稀释后）CTKBRYTM
| Q1 26 | — | $-0.83 | ||
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $340.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $341.7M | $122.9M |
| 总资产 | $461.5M | $442.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTKBRYTM
| Q1 26 | — | $340.6M | ||
| Q4 25 | $90.9M | $388.9M | ||
| Q3 25 | $93.3M | $416.1M | ||
| Q2 25 | $75.5M | $291.0M | ||
| Q1 25 | $95.3M | $314.5M | ||
| Q4 24 | $98.7M | $320.6M | ||
| Q3 24 | $162.3M | $298.4M | ||
| Q2 24 | $177.9M | $319.1M |
股东权益CTKBRYTM
| Q1 26 | — | $122.9M | ||
| Q4 25 | $341.7M | $139.1M | ||
| Q3 25 | $378.6M | $148.8M | ||
| Q2 25 | $377.6M | $-11.9M | ||
| Q1 25 | $379.6M | $18.9M | ||
| Q4 24 | $395.7M | $21.7M | ||
| Q3 24 | $385.5M | $11.2M | ||
| Q2 24 | $389.1M | $39.3M |
总资产CTKBRYTM
| Q1 26 | — | $442.3M | ||
| Q4 25 | $461.5M | $480.2M | ||
| Q3 25 | $494.9M | $506.9M | ||
| Q2 25 | $493.3M | $372.7M | ||
| Q1 25 | $482.6M | $386.7M | ||
| Q4 24 | $499.5M | $392.3M | ||
| Q3 24 | $491.2M | $363.6M | ||
| Q2 24 | $483.7M | $381.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | — |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | — |
| 自由现金流率自由现金流/营收 | -2.9% | — |
| 资本支出强度资本支出/营收 | 1.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.8M | — |
8季度趋势，按日历期对齐
经营现金流CTKBRYTM
| Q1 26 | — | — | ||
| Q4 25 | $-771.0K | $-25.4M | ||
| Q3 25 | $-3.9M | $-26.6M | ||
| Q2 25 | $108.0K | $-23.3M | ||
| Q1 25 | $-125.0K | $-40.4M | ||
| Q4 24 | $2.0M | $-18.8M | ||
| Q3 24 | $13.2M | $-25.2M | ||
| Q2 24 | $6.2M | $-29.1M |
自由现金流CTKBRYTM
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — |
自由现金流率CTKBRYTM
| Q1 26 | — | — | ||
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — |
资本支出强度CTKBRYTM
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — |
现金转化率CTKBRYTM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
RYTM
暂无分部数据
